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ABSTRACT 
During experimental sepsis in rodents after cecal ligation and puncture (CLP), excessive C5a is 
generated, leading to interactions with C5aR, loss of innate immune functions of neutrophils, and 
lethality. In the current study, we have analyzed the expression of the second C5a receptor C5L2, 
the putative default or nonsignaling receptor for C5a. Rat C5L2 was cloned, and antibody was 
developed to C5L2 protein. After CLP, blood neutrophils showed a reduction in C5aR followed 
by its restoration, while C5L2 levels gradually increased, accompanied by the appearance of 
mRNA for C5L2. mRNA for C5L2 increased in lung and liver during CLP. Substantially 
increased C5L2 protein (defined by binding of 125I-anti-C5L2 IgG) occurred in lung, liver, heart, 
and kidney after CLP. With the use of serum IL-6 as a marker for sepsis, infusion of anti-C5aR 
dramatically reduced serum IL-6 levels, while anti-C5L2 caused a nearly fourfold increase in IL-
6 when compared with CLP controls treated with normal IgG. When normal blood neutrophils 
were stimulated in vitro with LPS and C5a, the antibodies had similar effects on release of IL-6. 
These data provide the first evidence for a role for C5L2 in balancing the biological responses to 
C5a. 
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5a is a complement-derived anaphylatoxin containing 74 amino acids and exerts various 
proinflammatory effects such as chemotactic responses of neutrophils, release of granular 
enzymes from phagocytic cells, production of superoxide anion in neutrophils, histamine 
release from mast cells, vasodilatation, increased vascular permeability, and smooth muscle 
contraction (17). Excessive production of C5a occurs early in sepsis and leads to an unregulated 
proinflammatory response, ultimately resulting in multi-organ failure and tissue damage (1, 2, 8). 
In particular, innate immune functions of neutrophils, including chemotaxis, phagocytosis, and 
H2O2 production, are severely impaired (911). C5a blockade during both LPS- and cecal 
ligation and puncture (CLP)-induced sepsis was protective in rodents such as monkeys and rats. 
C 
Page 1 of 18
(page number not for citation purposes)
Blockade of C5a greatly reduced appearance of multi-organ failure in CLP rats (8, 10, 12, 13). 
These data suggest that increased generation of C5a plays an important role during the 
development of sepsis, compromising crucial innate-immune functions. 
The effects of C5a are mediated by its binding to its receptor, C5a receptor (C5aR, CD88), which 
is a G protein-coupled seven-transmembrane spanning receptor (14, 15). Expression of C5aR has 
been found on a variety of cells in many different organs and cells, including epithelial cells, 
endothelial cells, myeloid cells, and T cells (1623). During sepsis, vascular expression of C5aR 
is dramatically increased in lung, liver, kidney, and heart as a function of time (24). In addition, 
C5aR mRNA level is also elevated in all of these organs (24). Blockade of C5aR with antibody 
or a small molecular inhibitor (C5aRa) in CLP mice has been shown to greatly improve survival 
(24, 25), suggesting that the protective effects of C5a blockade were due to interception of 
C5a/C5aR signaling. 
Since its identification in early 1990, C5aR appeared to be the sole receptor for C5a. Recently, a 
second receptor for C5a, C5L2, has been described (2629). C5L2 is a high affinity receptor for 
both C5a and C5a des arg, and its expression on the human peripheral neutrophils is at levels 
similar to C5aR (26). Like C5aR, C5L2 has an acidic ligand binding N-terminal domain and a 
ligand activation domain (28). In contrast to C5aR, C5L2 is not coupled to intracellular G protein 
signaling pathways, possibly because of the substitution of Leu for Arg in the DRY sequence at 
the end of the third transmembrane segment and a shorter third intracellular loop lacking in 
Ser/Thr residues. When transfected into several cell lines, C5L2 is weakly phosphorylated after 
C5a binding and does not initiate increased calcium influx, stimulate chemotaxis, or activate 
MAP kinase (26, 28). Furthermore, in contrast to C5aR, C5a binding to C5L2 does not appear to 
result in internalization of the complex and demonstrates slow ligand on and off rates (26, 28). 
Such findings suggest that C5L2 may act as an unproductive, decoy, or scavenger receptor for 
C5a. 
Given the importance of C5a/C5aR signaling during sepsis in rodents, it was important to 
explore the function of C5L2 in sepsis. We cloned rat C5L2 and investigated expression of C5L2 
on surfaces of rat neutrophils and organs (lung, liver, kidney, heart) during sepsis, using in vivo 
binding studies with 125I-anti-C5L2 antibody (αC5L2) and real-time PCR analysis for mRNA of 
C5L2. In addition, we explored the effects of αC5L2 treatment on both in vitro and in vivo 
expression of IL-6. Our findings show for the first time that C5L2 is up-regulated during sepsis 
and that C5a interaction with C5L2 is negatively correlated with levels of expressed IL-6. This 
suggests that C5aR and C5L2 compete for C5a binding, the balance determining inflammatory 
mediator production. 
MATERIALS AND METHODS 
Peptide synthesis and production of anti-mouse C5aR and C5L2 antibodies 
A 37-amino acid peptide spanning the N terminus of the mouse C5aR 
(MDPIDNSSFEINYDHYGTMDPNIPADGIHLPKRQPGDC) and a 38-amino acid peptide spanning 
the N terminus of the mouse C5L2 (MMNHTTSEYYDYEYDHE HYSDLPDVPVDCPAGTCFTSD) 
were synthesized as described previously (21). The peptides were coupled to keyhole limpet hemocyanin 
by the glutaraldehyde method and used for the immunization of rabbits and the production of 
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immunoreactive anti-sera. The anti-peptide-specific antibody was either IgG-purified using 
ImmunoPure (A/G) IgG purification kit or affinity-purified using Aminolink plus immobilization 
kit by coupling the synthetic peptide to agarose support (Pierce, Rockford, IL) and was 
characterized by ELISA, flow cytometry, and Western blots for both mouse and rat C5L2. 
Cloning and expression of rat C5a 
Recombinant rat C5a was produced in our laboratory, using the pGEX expression vector for 
GST gene fusion (Amersham Pharmacia Biotech) (9). 
Cloning of full-length rat C5L2 
The full coding sequence of rat C5L2 was cloned from rat lung. Based on mouse C5L2 sequence, 
two deoxyoligonucleotides were designed (5′-GCTCGG 
CCGCTCGAGACCATGGACAACCACACCACCAGC-3′ and 5′-CCGAAACCGGA 
ATTCCACCGGCATCTCAGA-3′) and used to amplify a PCR product containing a portion of 
the rat C5L2 cDNA. The sequence at the 5′ end of the cDNA was obtained by 5′- RACE PCR 
(Invitrogen). The sequence at the 3′ end of the cDNA was obtained by a BLAST search of the 
NCBI Rat EST database (dbEST 14223745). 
Northern blot analysis 
Multiple tissue blots containing ~2 µg of poly (A) mRNA per lane (BD, Clontech) were 
sequentially hybridized with random primer 32P-labeled cDNAs spanning the coding regions of 
rat C5L2, C5aR, and actin. 
Transient expression of rat C5L2 in HEK293 cells 
HEK 293 cells were transiently transfected with pcDNA3.1C5L2 by Lipofectamine 2000. Forty-
eight hours after transfection, cells were used for immunostaining.  
Immunocytochemistry and confocal microscopy 
Rat C5L2-transfected HEK 293 cells or isolated rat blood neutrophils were fixed in 4% 
paraformaldehyde, and indirect immunofluorescence was performed as described previously (9). 
Anti-C5aR (αC5aR) or αC5L2 (10 µg/ml) was visualized with 15 µg/ml of goat anti-rabbit IgG 
conjugated to Alexa 568 (Molecular Probes). Cells were imaged using a confocal microscope 
(Olympus FV 500, Japan). No signal was detected in mock-transfected HEK 293 cells (data not 
shown). 
Rat model of CLP 
Male Long-Evans specific-pathogen-free rats (275-300 mg; Harlan, Indianapolis, IN) were used. 
After intraperitoneal administration of ketamine (20 mg/100 mg body wt.), the cecum was 
identified and ligated below the ileocecal valve. The cecum was then subjected to a single 
through-and-through perforation with an 18 gauge needle. After the bowel was repositioned, the 
abdomen was closed in layers, using a 4.0 surgical suture and metallic clips (Ethicon, 
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Somerville, NJ). Sham animals underwent the same procedure except for CLP. Before and after 
surgery, animals had unlimited access to food and water. 
Flow cytometric analysis 
C5aR or C5L2 content on blood neutrophils was evaluated by indirect immunofluorescence 
staining of whole blood using an established lyse/wash procedure (BD PharMingen). Flow 
cytometric analysis was carried out immediately after blood collection. One hundred microliters 
of rat whole blood were first incubated with 1 µg rat Fc Block (BD PharMingen) for 15 min and 
then stained with 20 µl of αC5aR or αC5L2 for 30 min. After being washed, the cells were 
labeled with Fluorescein Isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (1:50) 
(Biosource, Santa Clarita, CA). Erythrocytes were lysed for 10 min by addition of 1× fluorescent 
activated-substrate conversion (FASC) lysing solution (BD PharMingen). After being washed, 
the leukocytes were resuspended in a fixation solution (1% paraformaldehyde in PBS with 0.1% 
sodium azide). Granulocytes were gated by the typical forward and side light scatterprofiles. The 
same-gated population has been proven to be granulocytes by staining of whole blood with a 
FITC-labeled rat granulocyte marker, HIS48 (BD PharMingen) (9). 
Neutrophil isolation from rat whole blood and in vitro stimulation 
Whole blood from rats was drawn from the inferior vena cava into syringes containing the anti-
coagulant citrate dextrose (ACD; Baxter Health Care, Deerfield, IL). Neutrophils were isolated 
using Ficoll-Paque gradient centrifugation (Pharmacia Biotech, Uppsala, Sweden) followed by 
dextran sedimentation. Residual red blood cells were lysed using NH4Cl lysis buffer. Neutrophils 
were then resuspended in Dulbeccos modified Eagle medium (DMEM) containing 10% fetal 
bovine serum. For IL-6 study, neutrophils were first incubated with either 1 µg αC5aR or αC5L2 
at 37°C for 1 h and then stimulated with LPS (20 ng/ml) and C5a (10 nM) for 4 h. Supernatant 
fluids were collected after pelleting of the cells and were frozen at -80°C until used for ELISA 
analysis. 
RT-PCR analysis for C5L2 and C5aR 
Total RNAs from rat blood neutrophils at different stages of sepsis were isolated with the Trizol 
method (Life Technologies, Rockville, MD) according to the manufacturers instructions. 
Digestion of any contaminating DNA was achieved by treatment of samples with RQ1 Rnase-
free DNase (Promega, Madison, WI). Reverse transcription was performed with 0.5 µg RNA 
using the Superscript II RNase H- Reverse Transcriptase (Gibco-BRL, Grand Island, NY) according to 
the manufacturers protocol. PCR was then performed with primers for C5aR: 5′ primer, 5′-
TATAGTCCTGCCCTCGCTCAT-3′ and 3′ primer, 5′-TCACCACTTTGAGCGTCTTGG-3′; C5L2: 5′ 
primer, 5′-GCCTACCTCATAGT CCTGCT-3′ and 3′ primer, 5′-CAGTGGTGATGGTAACTTCC-3′. 
The primers for the housekeeping gene GAPDH were 5′ primer, 5′-GCCTCG TCT CAT AGA CAA 
GAT G-3′ and 3′ primer, 5′-CAG TAG ACT CCA CGA CAT AC-3′. After a hot-start for 5 min at 
94°C, 30 cycles were used for amplification with a melting temperature of 94°C, an annealing 
temperature of 60°C, and an extending temperature of 72°C, each for 1 min, followed by a final 
extension at 72°C for 8 min. The RT-PCR product was confirmed by electrophoresis of samples 
in 1.2% agarose gel. Control experiments were performed with the samples in which reverse 
transcriptase was not added to rule out contaminating DNA being responsible for any results. 
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Experimental CLP-induced sepsis in mice and organ preparation 
Seven- or eight-week-old specific pathogen-free male C57BL/6 mice were used. Approximately 
two-thirds of the cecum was ligated through a 1.5-cm abdominal midline incision. The ligated 
part of the cecum was punctured through and through with a 21 gauge needle. For the death of 
the animals, the inferior vena cava was incised and ~500 µl of blood were withdrawn. The chest 
was then opened, and the pulmonary artery was slowly perfused with 60 ml DPBS, the perfusion 
liquid being allowed to leak out of the open inferior vena cava after perfusion. Perfusion quality 
was optically controlled by observing the organ color change (to white) as the blood was 
completely removed. Thereafter, organs were removed for radioactivity analysis or snap-frozen 
for real-time PCR experiments. 
In vivo binding studies 
In vivo binding studies are described elsewhere (24). Briefly, 100 ng of 125I-labeled αC5aR or 
αC5L2 antibody and 2 µg of nonlabeled antibody as carrier in a total volume of 200 µl PBS were 
injected intravenously 15 min before death. Immediately after euthanization, lung, liver, kidney, 
and heart were thoroughly perfused and weighed. C5aR or C5L2 antibody binding was 
determined by using a gamma counter (1261 Multi; Wallac, Gaitherburg, MD) and expressed as 
counts per min (CPM) per gram tissue. 
Detection of C5aR/C5L2 mRNA in various organs during sepsis by SYBR green real-time 
quantitative PCR analysis 
Organs from mice were obtained 0, 3, 6, and 12 h after induction of CLP and prepared as 
described above. Total RNA was isolated with the Trizol method. Digestion of any 
contaminating DNA was achieved by treatment of samples with RQ1 RNase-Free DNase. 
Reverse transcription was performed with 1 µg RNA using the Superscript II RNase H Reverse 
Transcriptase. SYBR green real-time quantitative PCR was then performed with primers for C5aR: 5′ 
primer, 5′-GAAGCGGCAACCTGGGGATGT-3′ and 3′ primer, 5′ CGTCTGGCTC 
GAAGGCTGTCAC-3′; C5L2: 5′ primer, 5′-CTGGGCCTCTTGCTGACTGTGC-3′ and 3′ primer, 5′-
GCCCCAGGAAGCCAAAGAGGA-3′; GAPDH: 5′ primer, 5′ TACCCCCAATGTGTCCGTCGTG-
3′ and 3′ primer, 5′-CCTTCAGTGGGCCCTC AGATGC-3′. 
Detection of IL-6 in mouse serum by ELISA 
Blood was drawn from αC5aR, αC5L2, and control IgG-treated mice 6 h after CLP. The blood 
was allowed to clot on ice for 2 h before serum was obtained by centrifugation. Serum samples 
were subsequently analyzed for IL-6 using ELISA kits (BioSource International, Camarillo, CA) 
according to the manufacturers instructions. 
Statistical analysis 
All values were expressed as the means ± SE. Significance was assigned where P < 0.05. Data 
sets were analyzed using Students t test or one-way ANOVA, with individual group means 
being compared with the Student-Newman-Keuls multiple comparison test. 
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RESULTS 
5′-RACE PCR, cDNA cloning, and sequence comparison of the rat C5L2 with the sequence 
of other C5L2s 
Since C5L2 is expressed in both mouse and human lungs (26), we chose rat lung for cloning of rat C5L2. 
Using the mouse C5L2 nucleotide sequence, we designed two oligonucleotides (5′-
GCTCGGCCGCTCGAGACCATGGACAACCA CACCACCAGC-3′ and 5′-
CCGAAACCGGAATTCCACCGGCAT CTCAGA-3′) and PCR amplified an 865 bp cDNA fragment 
from rat lung. To obtain the full-length coding region of rat C5L2, we performed a BLAST search of the 
rat EST database using the partial rat C5L2 as the query sequence. One EST clone (dbEST 14223745) 
was obtained and contained an incomplete sequence of rat C5L2, terminating at the 3′-end with a poly 
(A) tail. To isolate sequences extending further upstream, we employed a 5′-RACE approach using a 
ligation-anchored rat lung cDNA template. A nested pair of primers was designed and two 
sequential rounds of PCR were carried out using two rat C5L2-specific nested primers in 
conjunction with adaptor primers. The amplification products of the 5′-RACE reaction were 
subcloned and sequenced. When the PCR products and the EST sequence were assembled 
together, we obtained the composite deduced amino acid sequence for C5L2 (Fig. 1A). This 
sequence was consistent with a full-length coding region based on a comparison with the human 
and mouse C5L2 sequences and the presence of a putative initiating ATG (Fig. 1, A and B). Two 
lines of evidence suggested that this ATG was the correct initiation site. First, the 5′-RACE data 
terminated at the same position in two independent 5′-RACE reactions, with the indicated ATG 
being the first potential initiation site in the sequence. Second, the sequence surrounding this 
ATG conforms with the consensus sequence for eukaryotic translation initiation sequences with 
a purine at position -3, the most critical residue for translation initiation. 
Comparison of the translation of the cDNA with other known C5L2 sequences showed that rat 
C5L2 is 59.8% identical to human C5L2 and 86.4% identical to mouse C5L2 (Fig. 1B). 
Hydropathy analysis confirmed that the cloned protein has seven transmembrane segments (data 
not shown). The N terminus of rat C5L2 contained several acidic amino acids, previously 
implicated to be a primary site for C5a binding to C5aR (30, 31). Like human and mouse C5L2, 
rat C5L2 did not have the DRY motif present in C5aR, and the third intracellular loop was much 
shorter than that of C5aR, suggesting that it poorly couples to G proteins (26, 28). 
Analysis of rat C5L2 mRNA expression in rat tissues and cells 
We further analyzed the expression of rat C5L2 mRNA in rat tissues using Northern blot 
analysis (Fig. 1C). Rat C5L2 and C5aR mRNAs were expressed in all tissues examined; while 
C5L2 mRNA showed highest expression in liver and thyroid, weaker expression was detected in 
brain, spleen, kidney, large intestine, and eye. In addition, RT-PCR analysis indicated that rat 
C5L2 mRNA was also present in lung alveolar macrophages and peripheral blood neutrophils 
(data not shown). To demonstrate cell surface expression of rat C5L2, we transfected a 
mammalian expression plasmid encoding rat C5L2 into HEK-293 cells and performed confocal 
fluorescence microscopy analysis. As shown in Fig. 1D, cells transfected with the rat C5L2 
demonstrated cell surface expression of C5L2 when αC5L2 was used. 
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Comparison of C5L2 expression to C5aR expression in neutrophils during CLP-induced 
sepsis 
Since recent findings suggest that compromised neutrophil functions during sepsis correlate with 
the reduction in C5aR content on neutrophil surfaces (9), we sought to determine if the 
expression of C5L2 on blood neutrophils was also changed during sepsis. Both C5L2 and C5aR 
content on rat blood neutrophils were quantitatively evaluated by flow cytometric analysis 0, 12, 
24, and 36 h after the onset of CLP. As shown in Fig. 2A, blood neutrophils from control animals 
(time 0) showed positive staining for both C5L2 and C5aR. During experimental sepsis, C5L2 
content on blood neutrophils was significantly increased 24 and 36 h after onset of CLP. In 
contrast, C5aR content on neutrophils significantly dropped (2.5-fold) 24 h after CLP and 
steadily increased thereafter, suggesting that surface C5L2 and C5aR may be independently 
regulated in blood neutrophils during sepsis. 
To determine the mechanism by which C5L2 content on neutrophils is regulated during sepsis, 
we evaluated C5L2 mRNA levels in purified neutrophils 0, 24, and 36 h after CLP. As shown in 
Fig. 2B, the C5L2 mRNA level dramatically increased 24 and 36 h after the onset of CLP, 
suggesting a transcriptional mechanism was involved in increased expression of C5L2. In 
contrast, C5aR mRNA levels showed no differences in blood neutrophils isolated at various time 
points after CLP (Fig. 2B). 
To visualize C5L2 changes in neutrophils during sepsis, we conducted confocal fluorescence 
microscopy analysis. As shown in Fig. 2C, in control cells both C5aR and C5L2 showed a 
uniform cortical pattern on the neutrophil periphery, indicative of membrane staining. In 
contrast, a diffuse pattern of staining was found in the cytoplasmic compartment in 24 h CLP 
neutrophils for C5aR, but not for C5L2, indicating that C5L2 did not undergo internalization as 
C5aR after CLP. 
Changed in vivo organ binding of 125I-αC5L2 during CLP-induced sepsis in mice 
Our previous work indicated up-regulation of C5aR protein in mouse lung, liver, heart, and 
kidney after CLP (24). To examine changes in C5L2 expression during sepsis, 125I-αC5L2 (4 
µCi), 125I-αC5aR (2 µCi), or 125I-preimmune IgG (2 µCi) were injected intravenously into mice 
at various time points (up to 12 h) after CLP. Total amounts of protein infused were 100 ng for 
αC5aR and αC5L2 and 2 µg for normal rabbit IgG. Details of this technique are described 
elsewhere (24). As shown in Fig. 3, A and B, each of the four organs, with the exception of C5L2 
in kidney showed increases in both C5aR and C5L2 content 12 h after CLP when compared with 
levels at time 0. In all but one case, the peak increases were at 12 h when compared with 3 and 6 
h after CLP (data not shown). In each case except the kidney, the increases at 12 h were 
statistically significant (P<0.05). In kidney, the peak increase, which was statistically significant, 
in C5L2 occurred at 3 h (data not shown). In all cases, the infusion of 125I-preimmune IgG at 0, 
3, 6, and 12 h after CLP showed no evidence of increased tissue localization (Fig. 3C). These 
data indicate that sepsis causes increases in both C5aR and C5L2 in organs that are targets of 
multi-organ failure (8). 
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Expression of mRNA for C5L2 during CLP-induced sepsis 
To extend the results from the in vivo binding experiments, we conducted quantitative real-time 
PCR experiments using RNA extracts from mouse organs. As shown in Fig. 4A, in each of the 
four organs studied, there was an increase in the amount of mRNA for C5aR during the CLP-
induced sepsis, roughly correlating with increased organ binding of 125I-αC5aR (Fig. 3A). In the 
lung and liver, an increased mRNA for C5L2 in the real-time PCR was only observed 12 h after 
CLP (Fig. 4B). In kidney and heart, there was no significantly increased level of C5L2 mRNA 
observed after the onset of CLP (Fig. 4B). These results suggested that the dynamic pattern of 
125I-αC5L2 binding to the various organs during sepsis may not solely be explained by an 
increased gene expression for C5L2 in these organs. 
Effects of αC5aR and αC5L2 on in vitro and in vivo production of IL-6 
Recent work from our laboratory (32) has shown that the co-presence of C5a with LPS induced 
enhanced production of IL-6 in blood neutrophils. To investigate the role of C5aR and C5L2 on 
IL-6 production, we conducted in vitro experiments with blood neutrophils obtained from 
healthy rats. As shown in Fig. 5A, C5a significantly augmented LPS-induced robust production 
of IL-6 in the presence of normal IgG. When neutrophils were preincubated with αC5aR IgG, 
the augmentation in IL-6 production related to costimulation with C5a disappeared. In dramatic 
contrast, neutrophil exposure to αC5L2 IgG dramatically increased production of IL-6 in 
neutrophils exposed to both LPS and C5a. To further extend these results, we measured IL-6 
levels in serum samples obtained 6 h after CLP in mice treated intravenously with preimmune 
IgG, αC5aR, or C5L2 IgG. The results are shown in Fig. 5B. As expected, serum IL-6 was 
elevated in mice 6 h after CLP. In αC5aR-treated mice, IL-6 levels were reduced to nearly 
undetectable levels 6 h after CLP when compared with control IgG-injected mice. In striking 
contrast, αC5L2-treated mice dramatically increased (by nearly fourfold) serum levels of IL-6, 
suggesting that there may be competition between C5aR and C5L2 for C5a binding, the balance 
determining serum levels of IL-6 during sepsis. Taken together, these results demonstrate that 
C5L2 may act as a high affinity decoy receptor, competing for C5a binding, to limit the 
inflammatory response caused by C5a interaction with C5aR. 
DISCUSSION 
The CLP model of sepsis in rodents closely reflects the clinical phases found in humans with 
sepsis, with an early hyperdynamic phase (tachycardia, increased cardiac output, and respiration, 
fever, leukocytosis, etc.) and a late hypodynamic phase (bradycardia, reduced cardiac output, 
hypothermia, leucopenia, etc.), (32) There is strong evidence for the adverse role of C5a in sepsis 
(33). Although much progress has been made in understanding the role of C5a and its receptor 
C5aR in sepsis, the many types of cells that can respond to C5a suggests that a multitude of 
biological responses may be triggered during sepsis. Recently, a second receptor for C5a, C5L2, 
was cloned from human and mouse (26, 28, 29), but its biological function is quite unclear. In 
this study, we report the cloning of rat C5L2 and describe changes in the expression and function 
of C5L2 in the setting of sepsis. The deduced amino acid sequence of this receptor is 59.8% 
identical to human C5L2 and 86.4% identical to mouse C5L2. Hydropathy analysis confirmed 
that the cloned protein has seven transmembrane segments (data not shown). As is the case for 
C5aR, C5L2 has an acidic ligand binding N-terminal domain and a ligand activation domain. 
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The substitution of leucine for arginine in the DRY sequence at the end of the third 
transmembrane segment in rat C5L2 and a shorter third intracellular loop devoid of Ser/Thr 
residues were found in rat C5L2, similar to human and mouse C5L2 (26, 28), suggesting this 
receptor does not mediate C5a signaling in rats. Northern blot and RT-PCR analysis of mRNA 
prepared from various tissues and myeloid cells revealed that C5L2 was expressed in a variety of 
rat tissues, in rat blood neutrophils, and in alveolar macrophages. The concordant expression 
pattern of C5L2 and C5aR mRNA suggests that C5L2 might exist as a binding protein 
competing with C5aR for C5a binding. 
Our recent work has shown that during the onset of CLP-induced sepsis, C5aR content on blood 
neutrophils significantly drops, reaching the lowest point at 24 h after CLP, presumably due to 
ligand-receptor internalization (9). Correspondingly, innate immune functions such as 
chemotaxis and the oxidative burst of neutrophils were substantially impaired (9). Beyond 24 h 
after CLP, blood neutrophils started to undergo a functional recovery, correlating with increased 
surface C5aR expression (9). In the current study, we demonstrate that C5L2 content on blood 
neutrophils significantly increases between 24 and 36 h after onset of CLP, suggesting that 
expression of C5L2 on blood neutrophils during sepsis is regulated differently from that of 
C5aR. It is well established that interaction of C5a with C5aR leads to rapid internalization of the 
receptor-ligand complex because of phosphorylation of serine residues of the receptor, while 
dephosphorylation of the receptor results its being recycled back to the surface of the cell (34-
36). Although excessive C5a appears to be produced during sepsis, the lack of phosphorylation 
of C5L2 after contact with C5a may be linked to the absence of internalization of the C5a/C5L2 
complex (26, 28). Our previous study demonstrated that neutrophils from 24 and 48 h CLP rats 
showed a nearly 400% increase in the surface content of C5a (10). Basing on this result and our 
current findings, it is possible that the substantial amounts of C5a on the surface of blood 
neutrophils during sepsis are due to C5a binding in a stationary manner to surface C5L2. 
We recently reported an increased in vivo binding of αC5aR and accompanying increased 
expression of mRNA for C5aR in mouse lung, liver, kidney, and heart after CLP-induced sepsis 
(24). We now report that the in vivo binding of αC5L2 was significantly increased in mouse 
lung, liver, and heart, but not kidney, 12 h after CLP when compared with levels at time 0. This 
suggests increases in C5L2 in multiple organs during sepsis. In addition, real-time PCR 
experiments showed dramatically increased mRNA expression for C5L2 in mouse liver and lung 
during sepsis. The biological implications of changes in C5a receptors during sepsis are not 
currently known but may be linked to development of multi-organ failure. Furthermore, whether 
the regulation of C5L2 expression in the different organs during sepsis is similar to that in 
neutrophils remains to be defined. Since it has been shown in an animal model of CLP-induced 
sepsis that lungs, liver, heart, and kidneys are targets for development of multiorgan failure, and 
blocking of C5a reduces the intensity of multi-organ failure (8), it is of great interest to explore if 
C5L2 plays a functional role in these organs during sepsis. 
Finally, we provide evidence that exposure of rat neutrophils to C5a and LPS results in 
dramatically increased release of IL-6 in the presence of αC5L2 (Fig. 5A). In contrast, blockade 
of C5aR significantly reduces in vitro IL-6 levels after cell stimulation by C5a and LPS. 
Furthermore, mice injected with αC5L2 at the start of CLP show dramatically increased serum 
levels of IL-6 when compared with control animals receiving nonspecific IgG. In contrast, serum 
levels of IL-6 are reduced to nearly undetectable levels in αC5aR-treated mice (Fig. 5B). These 
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results, coupled with our finding that there is increased surface expression of C5L2 on 
neutrophils during sepsis, suggest that C5L2 may have important functional roles during 
inflammatory events, behaving as a decoy (or scavenger) receptor for C5a, thereby limiting the 
inflammatory response caused by C5a binding to C5aR. 
Taken together, our results indicate that there is significantly increased expression of C5L2 (and 
C5aR) in lung, liver, kidney, and heart during CLP-induced sepsis in mice. Surface expression of 
C5L2 on blood neutrophils is also significantly increased during sepsis. Significantly amplified 
production of IL-6 occurs in vitro in neutrophils stimulated with C5a and LPS. After C5L2 
blockade in CLP mice, IL-6 levels are dramatically elevated. These data strongly suggest that, 
depending on the relative numbers of C5aR and C5L2, the generation of C5a may lead to an 
amplified pro-inflammatory response or a suppressed proinflammatory response. 
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Fig. 1 
 
   
 
Figure 1. Characteristics of rat C5L2. A) Deduced rat C5L2 open reading frame, which encodes a protein of 343 amino 
acids. B) Comparison of rat C5L2 to mouse and human C5L2 sequences. Black shaded areas indicate identity. C) Northern 
blot analysis of rat C5L2 and C5aR expression in various tissues. D) Cell surface expression of rat C5L2 in transiently 
transfected HEK 293 cells, as visualized by confocal microscopy. Rat C5L2 sequence data are available from 
GenBank/EMBL/DDBJ under accession no. AY600435. 
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Figure 2. Expression of C5L2 and C5aR on neutrophils during experimental sepsis. A) Whole blood samples from 
controls (normal rats) and CLP animals were stained with αC5L2 or αC5aR rabbit serum or pre-immune serum, and C5L2 
and C5aR content on blood neutrophils was evaluated by flow cytometric analysis at times indicated. Error bars are means 
± SE (n=4-6). B) RT-PCR for C5L2 and C5aR mRNA in rat blood neutrophils. RT-PCR was performed using total RNA 
from rat neutrophils isolated 0, 24, and 36 h after CLP. Equal loading of PCR product, as demonstrated by expression of 
GAPDH mRNA. Data represent 2 independent experiments with neutrophils pooled from 3-4 rats per time point. C) C5aR 
and C5L2 staining of blood neutrophils, as visualized by confocal microscopy. 
Page 15 of 18





Figure 3. In vivo binding of (A) 125I-αC5aR and (B) 125I-αC5L2 to organs 0 and 12 h after CLP. Binding is expressed as 
the ratio of counts per min (CPM) per gram organ from each animal obtained 15 min after intravenous injection of 125I-
αC5aR or 125I-αC5L2. C) In vivo binding of 125I-labeled pre-immune rabbit IgG to organs after CLP (data expressed in a 
similar way as in frames A and B). Error bars are means ± SE (n=4-5). 
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Fig. 4 
 
                  
 
Figure 4. Real-time PCR for C5aR (A) and C5L2 (B) mRNA in mouse lung, liver, kidney, and heart. PCR was performed 
using RNA isolated 0, 3, 6, and 12 h after CLP. Results were expressed as a ratio to GADPH and represent 3-6 animals for 
each time point. *Statistical significance in treated groups when compared with control animals. 
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Fig. 5 
 
                                
 
Figure 5. Effects of αC5L2 and αC5aR on in vitro production of IL-6 by blood neutrophils stimulated in vitro with LPS + 
C5a and serum levels of IL-6 6 h after CLP in rats treated with blocking antibodies to C5aR or C5L2. A) IL-6 as measured 
by ELISA analysis in supernatant fluids from blood neutrophils after in vitro incubation with C5a (10 nM) or LPS (20 
ng/ml) in the presence or absence of αC5L2 or αC5aR. Neutrophils were pooled from 4-6 animals per study; incubations 
were carried out in separate triplicate samples. B) ELISA measurements for serum IL-6 levels 6 h after CLP-induced sepsis 
in animals injected with αC5L2, αC5aR, or pre-immune IgG. IL-6 could not be detected in sera from control (normal) 
mice. When used, αC5L2 and αC5aR treatment consisted of 20 µg/mouse at the start of CLP, with a companion group 
treated with control IgG. Error are means ± SE (n=4). 
Page 18 of 18
(page number not for citation purposes)
